Krebs Biochemicals & Industries (NSE:KREBSBIO) Growth Rank: 4 (As of Jun. 24, 2026) — 100% Above Median


NSE:KREBSBIO Krebs Biochemicals & Industries Ltd NSE:KREBSBIO
38 GF Score
Price ₹65.45
GF Value ₹38.67
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Krebs Biochemicals & Industries Growth Rank?

Krebs Biochemicals & Industries NSE:KREBSBIO +1.38% 38 Growth Rank is 4 as of Jun. 24, 2026, which is 100% above its 10-year median of 2.00. GuruFocus rates NSE:KREBSBIO with a GF Score™ of 38/100 and a GF Value™ of ₹38.67 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Krebs Biochemicals & Industries has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Krebs Biochemicals & Industries Growth Rank Related Terms

NSE:KREBSBIO vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Krebs Biochemicals & Industries's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krebs Biochemicals & Industries Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Krebs Biochemicals & Industries's Growth Rank distribution charts can be found below:

* The bar in red indicates where Krebs Biochemicals & Industries's Growth Rank falls into.


NSE:KREBSBIO
38GF Score
Krebs Biochemicals & Industries Ltd NSE:KREBSBIO
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Krebs Biochemicals & Industries (NSE:KREBSBIO) has a Growth Rank of 4 as of Jun. 24, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Krebs Biochemicals & Industries and its competitors. This is 100% above median its historical median of 2.00. Over the past decade, Krebs Biochemicals & Industries' Growth Rank has ranged from 1.00 to 6.00.
Is Krebs Biochemicals & Industries' Growth Rank too high?
Krebs Biochemicals & Industries' current Growth Rank of 4 is 100% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. Overall, Krebs Biochemicals & Industries has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krebs Biochemicals & Industries' Growth Rank compare to ZTS?
Krebs Biochemicals & Industries' Growth Rank of 4 can be compared against companies in the Drug Manufacturers industry. Historically, Krebs Biochemicals & Industries' own Growth Rank has ranged from 1.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Krebs Biochemicals & Industries and its competitors. Krebs Biochemicals & Industries's current Growth Rank is 4, which is 100% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krebs Biochemicals & Industries stock overvalued right now?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries (NSE:KREBSBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹38.67, compared to a current price of ₹65.45 — trading 69.3% above its estimated fair value. The current Growth Rank is 4, which is 100% above median its 10-year median of 2.00. Krebs Biochemicals & Industries' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Krebs Biochemicals & Industries (NSE:KREBSBIO), the current Growth Rank is 4 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krebs Biochemicals & Industries (NSE:KREBSBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Krebs Biochemicals & Industries stock appears to be overvalued. The current stock price of ₹65.45 is trading 69.3% above its estimated GF Value™ of ₹38.67. GuruFocus considers Krebs Biochemicals & Industries to be Significantly Overvalued.

Key valuation signals for NSE:KREBSBIO:

  • Growth Rank: 4 (100% above median its 10-year median of 2.00)
  • GF Value™: ₹38.67 vs. price of ₹65.45 (69.3% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the NSE:KREBSBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krebs Biochemicals & Industries Business Description

Other Exchanges 524518:India
Address Kothapalli Village, Kasimkota Mandal, Anakapalli, Vishakapatnam, AP, IND, 531 031
Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.
38GF Score

Get the complete analysis for NSE:KREBSBIO

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹65.45
Price
₹38.67
GF Value